John Bradley, MD

Headshot of John Bradley, MD

John Bradley, MD
medical director
distinguished professor of Pediatrics

Academic appointment
  • Distinguished Professor of Pediatrics – Infectious Diseases
Clinical Areas
  • Pediatric Infectious Diseases
  •  Anti-infective therapeutics Clinical trials
  • Undergraduate: University of California Los Angeles, 1972
  • Medical School: University of California at Davis, 1976
  • Residency: Kaiser Foundation Hospital San Francisco, CA , 1979
  • Fellowship: Stanford University Medical Center, Stanford, CA, 1981
  • UCSD Department of Pediatrics Outstanding Teacher for Full-Time Faculty, 1988-89
  • UCSD Department of Pediatrics Outstanding Teacher for Full-Time Faculty, 1990-91
  • UCSD Department of Pediatrics Outstanding Teacher for Full-Time Faculty, 1994-95
  • UCSD Department of Pediatrics Outstanding Teacher for Full-Time Faculty, 2010-11
  • Rady Children’s Hospital San Diego Physicians of Excellence Award (Excellence in Teaching), 2012
  • UCSD School of Medicine Academy of Clinician Scholars, 2012
  • American Academy of Pediatrics Section on Infectious Diseases Award for Lifetime Contribution to Infectious Diseases Education, 2014
  • 2020 Distinguished Physician Award from Pediatric Infectious Disease Society
Clinical trials of new antimicrobials, antiviral (non-HIV), and antifungals, phase 1-4, focusing on new agents for multi-drug-resistant pathogens.

Computer modeling of antimicrobial drug exposure, based on concepts of pharmacokinetics/pharmacodynamics, integrating MIC frequency distributions in simulations to predict clinical and microbiologic success in treatment of infections in different body compartments.

Longitudinal Assessment of Beta-lactam Antibiotic Exposure in in Critically Ill Children with Sepsis (5R01HD095547-02)

Clinical trial design and regulatory science (a member of the FDA’s Advisor and Consultant’s Staff)
  1. Ambrose PG, Bhavnani SM, Andes DR, Bradley JS, Flamm RK, Pogue JM, Jones RN. Old In Vitro Antimicrobial Breakpoints Are Misleading Stewardship Efforts, Delaying Adoption of Innovative Therapies, and Harming Patients. Open Forum Infect Dis. 2020 Mar 13;7(7):ofaa084. doi: 10.1093/ofid/ofaa084. eCollection 2020 Jul. PMID: 32667364
  2. Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, Mueller BA, Pai MP, Wong-Beringer A, Rotschafer JC, Rodvold KA, Maples HD, Lomaestro BM. Executive Summary: Therapeutic Monitoring of Vancomycin for Serious Methicillin-Resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2020 Apr;40(4):363-367. doi: 10.1002/phar.2376. Epub 2020 Mar 29. PMID: 32227354
  3. Bradley JS, Stone GG, Chan PLS, Raber SR, Riccobene T, Mas Casullo V, Yan JL, Hendrick VM, Hammond J, Leister-Tebbe HK. Phase 2 Study of the Safety, Pharmacokinetics and Efficacy of Ceftaroline Fosamil in Neonates and Very Young Infants With Late-onset Sepsis. Pediatr Infect Dis J. 2020 May;39(5):411-418. doi: 10.1097/INF.0000000000002607. PMID: 32091493
  4. Avedissian SN, Skochko SM, Le J, Hingtgen S, Harvey H, Capparelli EV, Richardson A, Momper J, Mak RH, Neely M, Bradley JS. Use of Simulation Strategies to Predict Subtherapeutic Meropenem Exposure Caused by Augmented Renal Clearance in Critically Ill Pediatric Patients With Sepsis. J Pediatr Pharmacol Ther. 2020;25(5):413-422. doi: 10.5863/1551-6776-25.5.413. PMID: 32641911
  5. Bradley JS, Arrieta AC, Digtyar VA, Popejoy MW, Grandhi A, Bokesch P, Hershberger E, Dorr MB, Tan CM, Murata Y, Wolf DJ, Bensaci M. Daptomycin for Pediatric Gram-Positive Acute Hematogenous Osteomyelitis. Pediatr Infect Dis J. 2020 Sep;39(9):814-823. doi: 10.1097/INF.0000000000002790. PMID: 32639465
  6. Ericson JE, McGuire J, Michaels MG, Schwarz A, Frenck R, Deville JG, Agarwal S, Bressler AM, Gao J, Spears T, Benjamin DK Jr, Smith PB, Bradley JS; Best Pharmaceuticals for Children Actâ€"Pediatric Trials Network Steering Committee and the Clinical Trials Transformation Initiative. Hospital-acquired Pneumonia and Ventilator-associated Pneumonia in Children: A Prospective Natural History and Case-Control Study. Pediatr Infect Dis J. 2020 Aug;39(8):658-664. doi: 10.1097/INF.0000000000002642. PMID: 32150005
  7. Uyeki TM, Bernstein HH, Bradley JS, Englund JA, File TM, Fry AM, Gravenstein S, Hayden FG, Harper SA, Hirshon JM, Ison MG, Johnston BL, Knight SL, McGeer A, Riley LE, Wolfe CR, Alexander PE, Pavia AT. Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa. Clin Infect Dis. 2019 Mar 5;68(6):895-902. doi: 10.1093/cid/ciy874. PubMed PMID: 30834445.
  8. Noel GJ, Nambiar S, Bradley J; Clinical Trials Transformation Initiative’s Pediatric Antibiotic Drug Development Program. Advancing Pediatric Antibacterial Drug Development: A Critical Need to Reinvent our Approach. J Pediatric Infect Dis Soc. 2019 Mar 28;8(1):60-62. doi: 10.1093/jpids/piy001. Review. PubMed PMID: 29438520; PubMed Central PMCID: PMC6450364.
  9. Bradley JS, Broadhurst H, Cheng K, Mendez M, Newell P, Prchlik M, Stone GG, Talley AK, Tawadrous M, Wajsbrot D, Yates K, Zuzova A, Gardner A. Safety and Efficacy of Ceftazidime-Avibactam Plus Metronidazole in the Treatment of Children ≥3 Months to <18 Years With Complicated Intra-Abdominal Infection: Results From a Phase 2, Randomized, Controlled Trial. Pediatr Infect Dis J. 2019 Aug;38(8):816-824. Doi: 10.1097/INF.0000000000002392. PubMed PMID: 31306396.
  10. Bradley JS, Roilides E, Broadhurst H, Cheng K, Huang LM, MasCasullo V, Newell P, Stone GG, Tawadrous M, Wajsbrot D, Yates K, Gardner A. Safety and Efficacy of Ceftazidime-Avibactam in the Treatment of Children ≥3 Months to <18 Years With Complicated Urinary Tract Infection: Results from a Phase 2 Randomized, Controlled Trial. Pediatr Infect Dis J. 2019 Sep;38(9):920-928. doi: 10.1097/INF.0000000000002395. PubMed PMID: 31335570.
  11. Bradley JS, Ang JY, Arrieta AC, Larson KB, Rizk ML, Caro L, Yang S, Yu B, Johnson MG, Rhee EG. Pharmacokinetics and Safety of Single Intravenous Doses of Ceftolozane/Tazobactam in Children With Proven or Suspected Gram-Negative Infection. Pediatr Infect Dis J. 2018 Nov;37(11):1130-1136. doi: 10.1097/INF.0000000000002170. PubMed PMID: 30153232.
  12. Moodley A, Bradley JS, Kimberlin DW. Antiviral treatment of childhood influenza: an update. Curr Opin Pediatr. 2018 Jun;30(3):438-447. doi: 10.1097/MOP.0000000000000618. Review. PubMed PMID: 29745939.
  13. Le J, Bradley JS. Optimizing Antibiotic Drug Therapy in Pediatrics: Current State and Future Needs. J Clin Pharmacol. 2018 Oct;58 Suppl 10:S108-S122. doi:10.1002/jcph.1128. PubMed PMID: 30248202.
  14. Cherry JD, Wendorf K, Bregman B, Lehman D, Nieves D, Bradley JS, Mason WH, Sande-Lopez L, Lopez M, Federman M, Chen T, Blumberg D, Johnston S, Schwenk HT, Weintrub P, Quinn KK, Winter K, Harriman K. An Observational Study of Severe Pertussis in 100 Infants ≤120 Days of Age. Pediatr Infect Dis J. 2018 Mar;37(3):202-205. doi: 10.1097/INF.0000000000001710. PubMed PMID: 28737623.
  15. Bradley JS, Blumer JL, Romero JR, Michaels MG, Munoz FM, Kimberlin DW, Pahud B, DeBiasi RL, Yamamoto G, Roberts G, Hossain M, Shortino D, Yates PJ, Adams B, Peppercorn A. Intravenous Zanamivir in Hospitalized Patients With Influenza. Pediatrics. 2017 Nov;140(5). pii: e20162727. doi: 10.1542/peds.2016-2727. PubMed PMID: 29051331.
  16. Bradley J, Glasser C, Patino H, Arnold SR, Arrieta A, Congeni B, Daum RS, Kojaoghlanian T, Yoon M, Anastasiou D, Wolf DJ, Bokesch P. Daptomycin for Complicated Skin Infections: A Randomized Trial. Pediatrics. 2017 Mar;139(3). pii: e20162477. doi: 10.1542/peds.2016-2477. Epub 2017 Feb 15. PubMed PMID: 28202770.
  17. Thompson G, Barker CI, Folgori L, Bielicki JA, Bradley JS, Lutsar I, Sharland M. Global shortage of neonatal and paediatric antibiotic trials: rapid review. BMJ Open. 2017 Oct 13;7(10):e016293. doi: 10.1136/bmjopen-2017-016293. Review. PubMed PMID: 29030411; PubMed Central PMCID: PMC5652566.
  18. Marino NE, Davenport K, Hilfiker M, Langness S, Fairbanks T, Stucky Fisher E, Newbury R, Andrews A, Wells A, Chaparro JD, Bradley JS. Low Infection-Related Re-Admission Rates in a Retrospective of 4725 Children with Appendicitis Using a Clinical Pathway in a Tertiary Care Pediatric Center. Surg Infect (Larchmt). 2017 Nov/Dec;18(8):894-903. doi: 10.1089/sur.2017.104. Epub 2017 Oct 24. PubMed PMID: 29064344.
  19. Le J, Bradley JS, Hingtgen S, Skochko S, Black N, Jones RN, Lim M, Capparelli EV. Pharmacokinetics of single-dose ceftaroline fosamil in children with cystic fibrosis. Pediatr Pulmonol. 2017 Nov;52(11):1424-1434. doi: 10.1002/ppul.23827. Epub 2017 Sep 14. PubMed PMID: 28910514.
  20. Le J, Dam Q, Tran T, Nguyen A, Adler-Shohet FC, Kim S, Schmidt K, Lieberman JM, Bradley JS. Epidemiology and hospital readmission associated with complications of Staphylococcus aureus bacteremia in pediatrics over a 25-year period. Epidemiol Infect. 2017 Sep;145(12):2631-2639. doi: 10.1017/S0950268817001571. Epub 2017 Jul 27. PubMed PMID: 28748772.
  21. Avedissian SN, Bradley E, Zhang D, Bradley JS, Nazer LH, Tran TM, Nguyen A, Le J. Augmented Renal Clearance Using Population-Based Pharmacokinetic Modeling in Critically Ill Pediatric Patients. Pediatr Crit Care Med. 2017 Sep;18(9):e388-e394. doi: 10.1097/PCC.0000000000001228. PubMed PMID: 28640009.
  22. Riccobene TA, Khariton T, Knebel W, Das S, Li J, Jandourek A, Carrothers TJ, Bradley JS. Population PK Modeling and Target Attainment Simulations to Support Dosing of Ceftaroline Fosamil in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infections and Community-Acquired Bacterial Pneumonia. J Clin Pharmacol. 2017 Mar;57(3):345-355. doi: 10.1002/jcph.809. Epub 2016 Sep 27. PubMed PMID: 27510635.
  23. Bradley JS, Armstrong J, Arrieta A, Bishai R, Das S, Delair S, Edeki T, Holmes WC, Li J, Moffett KS, Mukundan D, Perez N, Romero JR, Speicher D, Sullivan JE, Zhou D. Phase I Study Assessing the Pharmacokinetic Profile, Safety, and Tolerability of a Single Dose of Ceftazidime-Avibactam in Hospitalized Pediatric Patients. Antimicrob Agents Chemother. 2016 Sep 23;60(10):6252-9. doi: 10.1128/AAC.00862-16. Print 2016 Oct. PubMed PMID: 27503642; PubMed Central PMCID: PMC5038276.
  24. Folgori L, Bielicki J, Ruiz B, Turner MA, Bradley JS, Benjamin DK Jr, Zaoutis TE, Lutsar I, Giaquinto C, Rossi P, Sharland M. Harmonisation in study design and outcomes in paediatric antibiotic clinical trials: a systematic review. Lancet Infect Dis. 2016 Sep;16(9):e178-e189. doi: 10.1016/S1473-3099(16)00069-4. Epub 2016 Jun 30. Review. PubMed PMID: 27375212.
  25. Cannavino CR, Mendes RE, Sader HS, Farrell DJ, Critchley IA, Biek D, Le J, Skochko SM, Jones RN, Bradley JS. Evolution of Ceftaroline-Resistant Mrsa in a Child with Cystic Fibrosis Following Repeated Antibiotic Exposure. Pediatr Infect Dis J. 2016 Jul;35(7):813-5. doi: 10.1097/INF.0000000000001171. PubMed PMID: 27093165.
  26. Cannavino CR, Nemeth A, Korczowski B, Bradley JS, O'Neal T, Jandourek A, Friedland HD, Kaplan SL. A Randomized, Prospective Study of Pediatric Patients With Community-acquired Pneumonia Treated With Ceftaroline Versus Ceftriaxone. Pediatr Infect Dis J. 2016 Jul;35(7):752-9. doi: 10.1097/INF.0000000000001159. PubMed PMID: 27093162.
  27. Blumer JL, Ghonghadze T, Cannavino C, O'Neal T, Jandourek A, Friedland HD, Bradley JS. A Multicenter, Randomized, Observer-blinded, Active-controlled Study Evaluating the Safety and Effectiveness of Ceftaroline Compared With Ceftriaxone Plus Vancomycin in Pediatric Patients With Complicated Community-acquired Bacterial Pneumonia. Pediatr Infect Dis J. 2016 Jul;35(7):760-6. doi: 10.1097/INF.0000000000001160. PubMed PMID: 27078119.
  28. Arnold JC, Bradley JS. Osteoarticular Infections in Children. Infect Dis Clin North Am. 2015 Sep;29(3):557-74. doi: 10.1016/j.idc.2015.05.012. Review. PubMed PMID: 26311358.
  29. Bradley JS, Kauffman RE, Balis DA, Duffy CM, Gerbino PG, Maldonado SD, Noel GJ. Assessment of musculoskeletal toxicity 5 years after therapy with levofloxacin. Pediatrics. 2014 Jul;134(1):e146-53. doi: 10.1542/peds.2013-3636. Epub 2014 Jun 2. PubMed PMID: 24918220.
  30. Bradley JS, Peacock G, Krug SE, Bower WA, Cohn AC, Meaney-Delman D, Pavia AT; AAP Committee on Infectious Diseases and Disaster Preparedness Advisory Council. Pediatric anthrax clinical management. Pediatrics. 2014 May;133(5):e1411-36. doi: 10.1542/peds.2014-0563. PubMed PMID: 24777226; PubMed Central PMCID: PMC4479255.
  31. Le J, Ngu B, Bradley JS, Murray W, Nguyen A, Nguyen L, Romanowski GL, Vo T, Capparelli EV. Vancomycin monitoring in children using bayesian estimation. Ther Drug Monit. 2014 Aug;36(4):510-8. doi: 10.1097/FTD.0000000000000039. PubMed PMID: 24452067; PubMed Central PMCID: PMC4101060.
  32. Hendricks KA, Wright ME, Shadomy SV, Bradley JS, Morrow MG, Pavia AT, Rubinstein E, Holty JE, Messonnier NE, Smith TL, Pesik N, Treadwell TA, Bower WA; Workgroup on Anthrax Clinical Guidelines. Centers for disease control and prevention expert panel meetings on prevention and treatment of anthrax in adults. Emerg Infect Dis. 2014 Feb;20(2). doi: 10.3201/eid2002.130687. PubMed PMID: 24447897; PubMed Central PMCID: PMC3901462.
  33. Chan MH, Ma L, Sidelinger D, Bethel L, Yen J, Inveiss A, Sawyer MH, Waters-Montijo K, Johnson JM, Hicks L, McDonald EC, Ginsberg MM, Bradley JS. The California Pertussis Epidemic 2010: A Review of 986 Pediatric Case Reports From San Diego County. J Pediatric Infect Dis Soc. 2012 Mar;1(1):47-54. doi: 10.1093/jpids/pis007. Epub 2012 Mar 1. PubMed PMID: 26618693.
  34. Bradley JS, Jackson MA; Committee on Infectious Diseases; American Academy of Pediatrics. The use of systemic and topical fluoroquinolones. Pediatrics. 2011 Oct;128(4):e1034-45. doi: 10.1542/peds.2011-1496. Epub 2011 Sep 26. PubMed PMID: 21949152.
  35. Bradley JS, Byington CL, Shah SS, Alverson B, Carter ER, Harrison C, Kaplan SL, Mace SE, McCracken GH Jr, Moore MR, St Peter SD, Stockwell JA, Swanson JT; Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Executive summary: the management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis. 2011 Oct;53(7):617-30. doi: 10.1093/cid/cir625. PubMed PMID: 21890766; PubMed Central PMCID: PMC3202323.


Bradley JS, Nelson JD, Barnett ED, Cantey JB, Kimberlin DW, Palumbo PE, Sauberan J, Smart JH,   Steinbach WJ, eds. 2021 Nelson’s Pediatric  Antimicrobial Therapy, 26th Edition, American Academy of Pediatrics, Elk Grove, Ill

Show additional content areas below